Skip to main content
Clinical Trials/ACTRN12620001292965
ACTRN12620001292965
Completed
Phase 1

A Phase 1, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses and Food Effect of PRAX-562 in Healthy Volunteers

Praxis Precision Medicines0 sites112 target enrollmentNovember 30, 2020

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Praxis Precision Medicines
Enrollment
112
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 30, 2020
End Date
July 28, 2021
Last Updated
4 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Female or male and between the ages of 18 and 55 years, inclusive.
  • \- Weight of at least 50 kg with body mass index (BMI) between 18 and 30 kg/m2 (inclusive).
  • \- Medically healthy (without significant medical issues, e.g. high blood pressure)

Exclusion Criteria

  • \- Ongoing or history of any psychiatric, medical or surgical condition that might jeopardize the participant’s safety or interfere with the absorption, distribution, metabolism or excretion of the study drug.
  • \- Any abnormal ECG findings, laboratory value or physical examination findings
  • \- Positive ethanol, drug screen or cotinine test
  • \- Use of systemic prescription medications or over\-the\-counter (OTC) medication, including multivitamins, and dietary and herbal supplement within 2 weeks
  • \- Use of any experimental or investigational drug or device within 30 days
  • \- Donation or loss of 400 mL or more of blood within 8 weeks and/or donation of plasma within 7 days

Outcomes

Primary Outcomes

Not specified

Similar Trials